0000950170-24-074032.txt : 20240617 0000950170-24-074032.hdr.sgml : 20240617 20240617092116 ACCESSION NUMBER: 0000950170-24-074032 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20240614 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240617 DATE AS OF CHANGE: 20240617 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Corbus Pharmaceuticals Holdings, Inc. CENTRAL INDEX KEY: 0001595097 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464348039 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37348 FILM NUMBER: 241047117 BUSINESS ADDRESS: STREET 1: 500 RIVER RIDGE DRIVE CITY: NORWOOD STATE: MA ZIP: 02062 BUSINESS PHONE: 617-963-0103 MAIL ADDRESS: STREET 1: 500 RIVER RIDGE DRIVE CITY: NORWOOD STATE: MA ZIP: 02062 FORMER COMPANY: FORMER CONFORMED NAME: SAV Acquisition Corp DATE OF NAME CHANGE: 20131220 8-K 1 crbp-20240614.htm 8-K 8-K
0001595097falseNONE00015950972024-06-142024-06-14

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 14, 2024

 

 

CORBUS PHARMACEUTICALS HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37348

46-4348039

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

500 River Ridge Drive

 

Norwood, Massachusetts

 

02062

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (617) 963-0100

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

CRBP

 

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 8.01 Other Events.

On June 14, 2024, Yong Ben M.D., a member of the board of directors of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), adopted a Rule 10b5-1 plan providing for the sale of up to 10,607 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). Pursuant to this plan, Dr. Ben may sell shares of Common Stock beginning on September 12, 2024, subject to the terms of the agreement, and the plan terminates on September 11, 2025. The trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Corbus Pharmaceuticals Holdings, Inc.

Date:

June 17, 2024

By:

/s/ Yuval Cohen

Name: Yuval Cohen
Title: Chief Executive Officer

 

 EX-101.SCH 2 crbp-20240614.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document And Entity Information
Jun. 14, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 14, 2024
Entity Registrant Name CORBUS PHARMACEUTICALS HOLDINGS, INC.
Entity Central Index Key 0001595097
Entity Emerging Growth Company false
Entity File Number 001-37348
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-4348039
Entity Address, Address Line One 500 River Ridge Drive
Entity Address, City or Town Norwood
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02062
City Area Code (617)
Local Phone Number 963-0100
Entity Information, Former Legal or Registered Name Not Applicable
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol CRBP
Security Exchange Name NONE
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - crbp-20240614.htm 8 crbp-20240614.htm crbp-20240614.xsd http://xbrl.sec.gov/dei/2024 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "crbp-20240614.htm": { "nsprefix": "crbp", "nsuri": "http://corbuspharma.com/20240614", "dts": { "inline": { "local": [ "crbp-20240614.htm" ] }, "schema": { "local": [ "crbp-20240614.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_5fae1a4b-2b23-443c-8172-9b72e69a97e7", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "crbp-20240614.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5fae1a4b-2b23-443c-8172-9b72e69a97e7", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "crbp-20240614.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://corbuspharma.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0000950170-24-074032-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-074032-xbrl.zip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end XML 15 crbp-20240614_htm.xml IDEA: XBRL DOCUMENT 0001595097 2024-06-14 2024-06-14 0001595097 false NONE 8-K 2024-06-14 CORBUS PHARMACEUTICALS HOLDINGS, INC. DE 001-37348 46-4348039 500 River Ridge Drive Norwood MA 02062 (617) 963-0100 Not Applicable false false false false Common Stock, par value $0.0001 per share CRBP false